Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
EAHAD 2024 – Interview with the Congress President
March 2024
EMJ sat down with EAHAD President, Wolfgang Miesbach, live at this year’s congress in Frankfurt, Germany. Miesbach highlighted key…
Read more
26th June 2015
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
26th June 2015
Adding elotuzumab to standard treatment for myeloma reduced disease progression
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
12th May 2015
Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas…
12th May 2015
Clinical significance of progenitor cells in multiple myeloma
Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth…
17th February 2015
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 3)
Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Andre Goy (John Theurer Cancer Center, Hackensack, NJ) at the 2014 American Society…
17th February 2015
ASH 2014: Recent investigational advances in mantle cell lymphoma treatment
Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the…
17th February 2015
ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)
Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance…
17th February 2015
Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 1)
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trněný (Charles…
Loading posts...
« Previous
1
…
3
4
5
6
Next »